Loading patent…
AssigneeInnogenetics N.V.
InventorsFons Bosman, Erik Depla, Geert Deschamps, Erwin Sablon, Manfred Suckow, Isabelle Samson, Gert Verheyden
Estimating the term…
The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70% are glycosylated with an oligomannose having a structure defined by Man(8 to 10)-GlcNAc(2). Furthermore, the ratio of the oligomannose with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10% of the oligomannoses is terminated with an α1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a Hansenula cell.
A composition comprising glycosylated HCV envelope proteins or glycosylated immunogenic fragments thereof, wherein said glycosylated HCV envelope proteins or glycosylated immunogenic fragments thereof are a yeast cell expression product, said glycosylated HCV envelope proteins or glycosylated immunogenic fragments thereof comprising N-glycosylated sites, said N-glycosylated sites being, on average, up to 80% core-glycosylated, said core-glycosylations containing less than 10% terminal α1,3 mannoses.
A composition comprising glycosylated HCV E1 envelope proteins and/or glycosylated HCV E2 envelope proteins or glycosylated immunogenic fragments thereof, wherein said glycosylated HCV E1 envelope proteins and/or glycosylated HCV E2 envelope proteins or glycosylated immunogenic fragments thereof are a Hansenula cell expression product, said glycosylated HCV E1 envelope proteins and/or glycosylated HCV E2 envelope proteins or glycosylated immunogenic fragments thereof comprising N-glycosylated sites, said N-glycosylated sites being, on average, up to 80% core-glycosylated, said core-glycosylations containing less than 10% terminal ccl α1,3 mannoses.
A composition comprising glycosylated HCV E1 envelope proteins and/or glycosylated HCV E2 envelope proteins or glycosylated immunogenic fragments thereof, said glycosylated HCV E1 envelope proteins and/or glycosylated HCV E2 envelope proteins or glycosylated immunogenic fragments thereof comprising N-glycosylated sites, said N-glycosylated sites being, on average, up to 80% core-glycosylated, said core-glycosylations containing less than 10% terminal α1,3 mannoses.
Dependencies are inferred from the claim text.